ChiaChi Hu

2.0k total citations · 1 hit paper
16 papers, 1.5k citations indexed

About

ChiaChi Hu is a scholar working on Immunology, Rheumatology and Surgery. According to data from OpenAlex, ChiaChi Hu has authored 16 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 5 papers in Rheumatology and 4 papers in Surgery. Recurrent topics in ChiaChi Hu's work include Psoriasis: Treatment and Pathogenesis (7 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Anesthesia and Pain Management (4 papers). ChiaChi Hu is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (7 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Anesthesia and Pain Management (4 papers). ChiaChi Hu collaborates with scholars based in Germany, Canada and United States. ChiaChi Hu's co-authors include Randall M. Stevens, Kim Papp, Jennifer Clay Cather, Georg Schett, Robert M. Day, J. Wollenhaupt, Robert Matheson, Stephen Hall, J. Crowley and A.B. Gottlieb and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and British Journal of Dermatology.

In The Last Decade

ChiaChi Hu

16 papers receiving 1.5k citations

Hit Papers

Treatment of psoriatic arthritis in a phase 3 randomised,... 2014 2026 2018 2022 2014 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
    2014 341 citations Arthur Kavanaugh, Philip J. Mease et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
ChiaChi Hu Germany 10 1.2k 733 397 381 217 16 1.5k
G Tessari Italy 8 603 0.5× 176 0.2× 45 0.1× 333 0.9× 223 1.0× 8 994
Rocío Prieto‐Pérez Spain 17 384 0.3× 78 0.1× 44 0.1× 157 0.4× 34 0.2× 21 591
Peter Bias Germany 18 142 0.1× 168 0.2× 116 0.3× 43 0.1× 83 0.4× 44 1.0k
Csilla Sipeky Hungary 18 187 0.2× 89 0.1× 76 0.2× 29 0.1× 183 0.8× 39 723
Victor Ginsberg United States 9 150 0.1× 280 0.4× 178 0.4× 55 0.1× 54 0.2× 21 647
Rachel Lorier United States 10 247 0.2× 77 0.1× 69 0.2× 32 0.1× 363 1.7× 13 698
Junlong Li China 12 239 0.2× 36 0.0× 28 0.1× 114 0.3× 90 0.4× 43 578
I. Arias de la Rosa Spain 16 371 0.3× 391 0.5× 125 0.3× 7 0.0× 291 1.3× 44 841
Carolyn R. Lew United States 14 96 0.1× 75 0.1× 37 0.1× 40 0.1× 162 0.7× 29 471
P. B. B. Jones New Zealand 14 159 0.1× 152 0.2× 59 0.1× 9 0.0× 174 0.8× 21 724

Countries citing papers authored by ChiaChi Hu

Since Specialization
Citations

This map shows the geographic impact of ChiaChi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by ChiaChi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites ChiaChi Hu more than expected).

Fields of papers citing papers by ChiaChi Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by ChiaChi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by ChiaChi Hu. The network helps show where ChiaChi Hu may publish in the future.

Co-authorship network of co-authors of ChiaChi Hu

This figure shows the co-authorship network connecting the top 25 collaborators of ChiaChi Hu. A scholar is included among the top collaborators of ChiaChi Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with ChiaChi Hu. ChiaChi Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Cutolo, Maurizio, Roy Fleischmann, Frédéric Lioté, et al.. (2016). A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. The Journal of Rheumatology. 43(9). 1724–1734. 163 indexed citations
3.
4.
Paul, C., Jennifer Clay Cather, Melinda Gooderham, et al.. (2015). Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). British Journal of Dermatology. 173(6). 1387–1399. 350 indexed citations
5.
6.
7.
Kavanaugh, Arthur, Philip J. Mease, Juan J. Gómez‐Reino, et al.. (2014). Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Annals of the Rheumatic Diseases. 73(6). 1020–1026. 341 indexed citations breakdown →
8.
Adebajo, Adewale, Arthur Kavanaugh, Philip J. Mease, et al.. (2014). 217. Long-Term 52-Week Results of Palace 1, A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase Inhibitor, In atients with Psoriatic Arthritis. Lara D. Veeken. 53(suppl_1). i141–i141. 2 indexed citations
9.
Edwards, Christopher J, Francisco J. Blanco, Jeffrey Crowley, et al.. (2014). 212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement. Lara D. Veeken. 53(suppl_1). i138–i139. 27 indexed citations
10.
11.
Gottlieb, Alice B., Robert Matheson, Alan Menter, et al.. (2013). Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.. PubMed. 12(8). 888–97. 65 indexed citations
12.
Strand, Vibeke, Georg Schett, ChiaChi Hu, & Randall M. Stevens. (2013). Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study. The Journal of Rheumatology. 40(7). 1158–1165. 35 indexed citations
13.
Strand, Vibeke, David Fiorentino, ChiaChi Hu, et al.. (2013). Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health and Quality of Life Outcomes. 11(1). 82–82. 60 indexed citations
14.
Schett, Georg, J. Wollenhaupt, Kim Papp, et al.. (2012). Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism. 64(10). 3156–3167. 162 indexed citations
15.
Papp, Kim, Jennifer Clay Cather, Howard Sofen, et al.. (2012). Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. The Lancet. 380(9843). 738–746. 217 indexed citations
16.
Papp, Kim, Roland Kaufmann, Diamant Thaçi, et al.. (2012). Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison study. Journal of the European Academy of Dermatology and Venereology. 27(3). 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G Tessari Breakdown of academic impact, for papers by Rocío Prieto‐Pérez Breakdown of academic impact, for papers by Peter Bias Breakdown of academic impact, for papers by Csilla Sipeky Breakdown of academic impact, for papers by Victor Ginsberg Breakdown of academic impact, for papers by Rachel Lorier Breakdown of academic impact, for papers by Junlong Li Breakdown of academic impact, for papers by I. Arias de la Rosa Breakdown of academic impact, for papers by Carolyn R. Lew Breakdown of academic impact, for papers by P. B. B. Jones
Rankless by CCL
2026